

Case Investigation Form Coronavirus Disease (COVID-19)



Version 9

- 1) The Case Investigation Form (CIF) is meant to be administered as an interview by a health care worker or any personnel of the DRU. This is not a self-administered questionnaire.
- 2) Please be advised that DRUs are only allowed to obtain 1 copy of accomplished CIF from a patient.
- 3) Please fill out all blanks and put a check mark on the appropriate box. Never leave an item blank (write N/A). Items with * are required fields. All dates must be in MM/DD/YYYY format.

Disease Reporting Unit*					DRU Region and Province					PhilHealth No.*						
testing					adas					asdas						
Name of Interviewer					Contact Number of Interviewer					Date of Interview (MM/DD/YYYY)*						
									-22-21							
Name of Informant (if applicable)					elationship				Contact Number of Informant							
1,7,7	•				•											
		Not applic	able (Nev	/ case)			pdate case classific	ation		Update disposit	ion					
If existing case		Not applic		,		- u	pdate vaccination			Update exposur		story				
(check all that apply)*		Update sy	mptoms			■ (pdate lab result			Others, specify:		·				
	╽┇	Update he	ealth statu	s / outco	ome	□ (pdate chest imagin	g findings		adsaa						
Type of Client*	COVID-19	Case (Sus	pect, Pro	bable, or Conf	firmed)	Close Conta	ict	☐ For RT-PCR Testing (Not a Case of Close Contact)								
Testing Category/Subgroup* (Check all that apply, refer to Appendix 2) ■ A □ B □ C □ D □ E ■ F □ G □ H □ I □											ı 🗆 J					
Double Daking blofarmaking																
Part 1. Patient Informat																
1.1. Patient Prof	ile			1		- 40 11			T							
Last Name* Salcedo				Fit	rst Name (and	Suffix)* E	Baldwin		Middle Name* Eugenio							
Birthday (MM/DD/YYYY)* 08/05/1996					ge*25				Sex*	☐ Male	<u>Ω</u> Γ	Female				
Civil Status undefined		-,			ationality*											
Occupation				W	orks in a close	d setting	? ☐ Yes		□ No □ Unknown							
1.2. Current Address in the Philippines and Contact Information* (Provide address of institution if patient lives in closed settings, see 1.5)																
House No./Lot/Bldg.*			Street/F	urok/Sit	io*		Barangay*			Municipality/Cit	ty*					
335				M	lagdalo			Potol			Kawit					
Province*			Home P		. (& Area Code	;)	Cellphone No.	*		Email Address						
					. (0.7 0 0000	-,	Compriorie ivo			2						
Cavite																
1.3. Permanent /	Addres	s and Conta				current	1									
House No./Lot/Bldg. Str				urok/Sit	io		Barangay	Barangay			Municipality/City					
Province Home Phon				hone No	. (& Area Code	2)	Cellphone No.	Cellphone No.			Email Address					
1.4. Current Wor	rkplace	Address ar	nd Contac	t Informa	ation											
Lot/Bldg. Street					Barangay					Municipality/Cit	lity					
Province Name of We				f Workpl	ace		Phone No./Cel	Phone No./Cellphone No.			Email Address					
1.5. Special Popu	ulation	(indicate fu	irther det	ails on e	xposure and tr	avel hist	ory in Part 3)									
Health Care Worker*		☐ Yes,	name of I	nealth fa	cility:	and location:					Ω	No				
											No					
Returning Overseas Filipino* Yes, country of ori OFW:					OFW		Non-OFW	port number.			~	110				
Foreign National Travele	er*	☐ Yes,	country c	f origin:			and Pass	port number:				No				
Locally Stranded Individual / Yes, City, Municipality, & Province of origin									No							
APOR / Local Traveler*			Locally	Strande	d Individual		☐ Aut	thorized Perso	n Outside Res	idence / Local Tra	veler					
Lives in Closed Settings* Yes, institution type: and name:									No							
Lives in closed settings.		(e.g.	prisons, re	<u>sidential</u>	facilities, retire	ment con	munities, care home	s, camps, etc.)								
D																
Part 2. Case Investigation																
2.1. Consultation							l. /4.44.4/DD /\0000*									
Have previous COVID-19				Ω	res, pate of Fil	ısı consu	lt (MM/DD/YYYY)*				Ω	No				
Name of facility where fi																
2.2. Disposition		of Report*	(Provide	name of	f hospital/isola	ation/qu										
Admitted in hospit							Date and Time ad	mitted in hos	oital							
Admitted in isolation/quarantine facility Date and Time isolated/quarantined in facility																
☐ In home isolation/quarantine						Date and Time isolated/quarantined at home										
Discharged to home If discharged: Date of Discharge (MM/DD/YYYY)* Discharged to home																
							_									
2.3. Health Status at Consult* (Refer to Appendix			•	☐ Asympt		☐ Mild				☐ Severe ☐ Critical						
2.4. Case Classifi			ppendix 1		☐ Suspect	t	☐ Probable	☐ Con	firmed	☐ Non-COVID-1	.9 Case					
2.5. Vaccination information*																
Date of vaccination*	Na	me of Vacci	ne*	Dose no	umber (e.g. 1st,	2 nd)*	Vaccination cer	nter/facility	Region	of health facility	Adverse	e event/s?				
							<u> </u>				☐ Yes	□ No				
											☐ Yes	□ No				

2.6. Clinical Information																		
Date of Onset of Illne	ss (MM/	DD/YYY	Y)*		_	C - - - - - -	: (Chl		l - : f	41								
Signs and Symptoms	Comorbidities (Check all that apply if present)																	
☐ Asymptomatic	□ None □ Gastrointestinal																	
☐ Fever °C ☐ Anorexia							☐ Hypertension ☐ Genito-urinary											
•								☐ Diabetes ☐ Heart Disease					☐ Neurological Disease					
General weakness U Vomiting Fatigue Diarrhea							Disease				Cance							
☐ Fatigue ☐ Diarrhea ☐ Headache ☐ Altered Mental Status																		
☐ Myalgia ☐ Anosmia (loss of smell, w/o any identified cause)										VI/UU/YYY	Y)			□ No				
☐ Sore throat ☐ Ageusia (loss of taste, w/o any identified cause)						High-risk pr		☐ Ye			□ No							
☐ Coryza ☐ Others, specify							sed to have S	Severe Ac	ute Respira	tory Illnes	s?	☐ Yes		□ No				
Chest imaging findings																		
	naging do		Results O Normal	Chast radia		manisian after			ماهندي بمعاما	سم ما مانسم م	المصماا	laau lau a	d: a.t.					
☐ Chest radiography ☐ Normal ☐ Chest radiography: Hazy opacities, often rounded in morphology, with peripheral and lower lung dist. ☐ Chest CT ☐ Pending ☐ Chest CT: Multiple bilateral ground glass opacities, often rounded in morphology, w/ peripheral & lower lung dist.												lung dist						
☐ Lung ultrasound ☐ Lung ultrasound: Thickened pleural lines, B lines, consolidative patterns with or without air bronchograms													-					
☐ None ☐ Other findings, specify																		
2.7. Laboratory Information																		
Have tested positive using Yes, date of specimen Collection (MM/DD/YYYY)* No																		
RT-PCR before? * Laboratory* No. of previous RT-PCR swabs done																		
Date collected* Date	released Laboratory* Type of test*										Resu	ults*						
					RT-PCR (OF	,	⊃ Antige	n; reason)			Pending		Negative				
						•		nd of kit :ibody Test			_ 0	Positive		Equivocal				
				۵		•	J AIILIDO	dy lest				Others:						
) Antige	n: reason	1			Pending	D	Negative				
				ō	•	,					ā	Positive	Ö	Equivocal				
						PS and NPS)		dy Test				Others:		•				
				٥	Others:					-								
2.8. Outcome/	Conditio	n at Tin	ne of Report*															
☐ Active (currently a	dmitted/	isolatio	n/quarantine) 🛭 🗗 F	Recovered, d	ate of recover	y (MM/DD/YYYY)	*		Died, da	ate of dea	th (MM	1/DD/YYYY)* _						
If died,	Imme	nmediate Cause:					Antecede	nt Cause	::									
cause of death*	I I a al a a	de des es Co					Contributor											
	Under	lying Ca	ause:				Contribut	ory Cond	aitions:									
PART 3. Contact Traci	ng: Fxpo	sure an	d Travel History															
History of exposure to				OVID-19 cas	e 14 days hefo	ore the onset	☐ Yes	t date of	flast conta	ct /AAA/D	n/vvvv	′)*						
of signs and symptom:								-	i iast conta		nknowi			_				
			-		-			s, Interna	ational		s, Loca							
Has the patient been in a place with a known COVID-19 transmission 14 days before t signs and symptoms? OR If Asymptomatic, 14 days before swabbing or specimen colle							□ No		ational			n exposure						
If International Travel, If International Travel, If International Travel,																		
country of origin				With o	ongoing COVID	0-19 community transmission?												
Airline/Sea vessel Flight/Vessel Number						Date of departure (MM/DD/YYYY) Date of arrival in PH (MM/DD/YYYY)								YY)				
·												•						
If Local Travel, specify	travel nl:	ares (Ch	eck all that annly n	ovide name	of facility, add	lress and inclu	sive travel	dates in I	MM/DD/VV	/V)								
	traver pri	1003 (01		ovide Hairie	oj jučinty, uda	Address	SIVE LIUVEI		Inclusive T	-	es	With or	ngoing	COVID-19				
Place Visited			Name of Place	(Region, Pr	Province, Municipality/City) From: To:						With ongoing COVID-19 Community Transmission?							
☐ Health Facility												☐ Yes		□ No				
☐ Closed Settings												☐ Yes		□ No				
☐ School										-		☐ Yes		□ No				
☐ Workplace								-		-		☐ Yes		□ No				
☐ Market												☐ Yes		□ No				
☐ Social Gathering		<u></u>										☐ Yes		□ No				
☐ Others												☐ Yes		□ No				
☐ Transport Service, specify the following:																		
Airline / Sea vessel / Bu	Departure	Date (MM/D	DD/YYYY)	De	stination		Date of Arri	val (Mi	M/DD/YYYY)									
											T		· <u></u>					
				1		+			†									
											Contact Number							
Name (Use					e the back pag	ıe ij needed)		Co	nract l	number							
were with the patient	two days	prior t	o onset of illness unt	il this date														
- If asymptomatic, provide names and contact numbers of persons who																		
were with the patient on the day specimen was submitted for testing until this date																		
until tills date																		

SUSPECT

A) A person who meets the clinical AND epidemiological criteria

Clinical criteria:

- 1) Acute onset of fever AND cough OR
- Acute onset of ANY THREE OR MORE of the following signs or symptoms; fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia / nausea/ vomiting, diarrhea, altered mental status. AND

- Epidemiological criteria

- Residing/working in an area with high risk of transmission of the virus (e.g closed residential settings and humanitarian settings, such as camp and camp-like setting for displaced persons), any time w/in the 14 days prior to symptoms onset OR
- 2) Residing in or travel to an area with community transmission anytime w/in the 14 days prior to symptoms onset; OR
- Working in health setting, including w/in the health facilities and w/in households, anytime w/in the 14 days prior to symptom onset;

 OR
- B) A patient with severe acute respiratory illness (SARI: acute respiratory infection with history of fever or measured fever of ≥ 38°C; cough with onset w/in the last 10 days; and who requires hospitalization)

PROBABLE

- A) A patient who meets the clinical criteria (on the left) AND is contact of a probable or confirmed case, or epidemiologically linked to a cluster of cases which had had at least one confirmed identified within that cluster
- B) A suspect case (on the left) with chest imaging showing findings suggestive of COVID-19 disease. Typical chest imaging findings include (Manna, 2020):
 - Chest radiography: hazy opacities, often rounded in morphology, with peripheral and lower lung distribution
 - Chest CT: multiple bilateral ground glass opacities, often rounded in morphology, with peripheral and lower lung distribution
 - Lung ultrasound: thickened pleural lines, B lines (multifocal, discrete, or confluent), consolidative
 patterns with or without air bronchograms
- C) A person with recent onset of anosmia (loss of smell), ageusia (loss of taste) in the absence of any other identified cause
- D) Death, not otherwise explained, in an adult with respiratory distress preceding death AND who was a contact of a probable or confirmed case or epidemiologically linked to a cluster which has had at least one confirmed case identified with that cluster

CONFIRMED

A person with laboratory confirmation of COVID-19 infection,

irrespective of clinical signs and symptoms.

Appendix 2. Testing Category / Subgroup

- A Individuals with severe/critical symptoms and relevant history of travel/contact
- Individuals with mild symptoms, relevant history of travel/contact, and considered vulnerable; vulnerable populations include those elderly and with preexisting medical conditions that predispose them to severe presentation and complications of COVID-19
- C Individuals with mild symptoms, and relevant history of travel and/or contact
 - Individuals with **no symptoms** but with **relevant history** of travel and/or contact or high risk of exposure. These include:
- D1 Contact-traced individuals

D

- D2 Healthcare workers, who shall be prioritized for regular testing in order to ensure the stability of our healthcare system
- D3 Returning Overseas Filipino (ROF) workers, who shall immediately be tested at port of entry
- Filipino citizens in a specific locality within the Philippines who have expressed intention to
 return to their place of residence/home origin (Locally Stranded Individuals) may be tested subject to the existing protocols of the IATF
- E Frontliners indirectly involved in health care provision in the response against COVID-19 may be tested as follows:
- E1 Those with high or direct exposure to COVID-19 regardless of location may be tested up to once a week. These include: (1) Personnel manning the Temporary Treatment and Quarantine Facilities (LGU and Nationally-managed); (2) Personnel serving at the COVID-19 swabbing center; (3) Contact tracing personnel; and (4) Any personnel conducting swabbing for COVID-19 testing
- Those who do not have high or direct exposure to COVID-19 but who live or work in Special Concern Areas may be tested up to every two to four weeks. These include the following: (1) Personnel manning Quarantine Control Points, including those from Armed Forces of the Philippines, Bureau of Fire Protection; (2) National / Regional / Local Risk Reduction and Management Teams; (3) Officials from any local government / city / municipality health office (CEDSU, CESU, etc.); (4) Barangay Health Emergency Response Teams and barangay officials providing barangay border control and performing COVID-19-related tasks; (5) Personnel of Bureau of Corrections and Bureau of Jail Penology & Management; (6) Personnel manning the One-Stop-Shop in the Management of ROFs; (7) Border control or patrol officers, such as immigration officers and the Philippine Coast Guard; and (8) Social workers providing amelioration and relief assistance to communities and performing COVID-19-related tasks
- Other vulnerable patients and those living in confined spaces. These include but are not limited to: (1) Pregnant patients who shall be tested during the peripartum period; (2) Dialysis patients; (3) Patients who are immunocompromised, such as those who have HIV/AIDS, inherited diseases that affect the immune system; (4) Patients undergoing chemotherapy or radiotherapy; (5) Patients who will undergo elective surgical procedures with high risk for transmission; (6) Any person who have had organ transplants, or have had bone marrow or stem cell transplant in the past 6 months; (7) Any person who is about to be admitted in enclosed institutions such as jails, penitentiaries, and mental institutions.

- Residents, occupants or workers in a localized area with an active COVID-19 cluster, as identified and declared by the local chief executive in accordance with existing DOH Guidelines and consistent with the National Task Force Memorandum Circular No. 02 s.2020 or the Operational Guidelines on the Application of the Zoning Containment Strategy in the Localization of the National Action Plan Against COVID-19 Response. The local chief executive shall conduct the necessary testing in order to protect the broader community and critical economic activities and to avoid a declaration of a wider community quarantine.
- Frontliners in Tourist Zones:
- H1 All workers and employees in the hospitality and tourism sectors in El Nido, Boracay, Coron, Panglao, Siargao and other tourist zones, as identified and declared by the Department of Tourism. These workers and employees may be tested once every four (4) weeks.
- H2 All travelers, whether of domestic or foreign origin, may be tested at least once, at their own expense, prior to entry into any designated tourist zone, as identified and declared by the Department of Tourism.
- All workers and employees of manufacturing companies and public service providers registered in economic zones located in Special Concern Areas may be tested regularly.
- J Economy Workers
- J1 Frontline and Economic Priority Workers, defined as those 1) who work in high priority sectors, both public and private, 2) have high interaction with and exposure to the public, and 3) who live or work in Special Concerns Areas, may be tested every three (3) months. These include but not limited to:
 - **Transport and Logistics**: drivers of taxis, ride hailing services, buses, public transport vehicle, conductors, pilots, flight attendants, flight engineers, rail operators, mechanics, servicemen, delivery staff, water transport workers (ferries, inter-island shipping, ports)
 - Food Retails: waiters, waitress, bar attendants, baristas, chefs, cooks, restaurant managers
 - Education: teachers at all levels of education and other school frontliners such as guidance counselors, librarians, cashiers
 - Financial Services: bank tellers
 - Non-Food Retails: cashiers, stock clerks, retail salespersons
 - **Services**: hairdressers, barbers, manicurists, pedicurists, massage therapists, embalmers, morticians, undertakers, funeral directors, parking lot attendants, security guards, messengers
 - Construction: construction workers including carpenters, stonemasons, electricians, painters, foremen, supervisors, civil engineers, structural engineers, construction managers, crane/tower operators, elevator installers, repairmen
 - Water Supply, Sewerage, Waster Management: plumbers, recycling/ reclamation workers, garbage collectors, water/wastewater engineers, janitors, cleaners
 - **Public Sector**: judges, courtroom clerks, staff and security, all national and local government employees rendering frontline services in special concern areas
 - Mass Media: field reporters, photographers, cameramen
- All employees **not covered above are not required to undergo testing but are encouraged to be**12 **tested every quarter.** Private sector employers are highly encouraged to send their employees for regular testing at the employers' expense
 - in order to avoid lockdowns that may do more damage to their companies

Appendix 3. Severity of the Disease

MILD

Symptomatic patients presenting with fever, cough, fatigue, anorexia, myalgias; other non-specific symptoms such as sore throat, nasal congestion, headache, diarrhea, nausea and vomiting; loss of smell (anosmia) or loss of taste (ageusia) preceding the onset of respiratory symptoms with NO signs of pneumonia or hypoxia

MODERATE

- Adolescent or adult with clinical signs of non-severe pneumonia (e.g. fever, cough, dyspnea, respiratory rate (RR) = 21-30 breaths/minute, peripheral capillary oxygen saturation (SpO2) >92% on room air)
- Child with clinical signs of non-severe pneumonia (cough or difficulty of breathing and fast breathing [< 2 months: > 60; 2-11 months: > 50; 1-5 years: > 40] and/or chest indrawing)

SEVERE

- Adolescent or adult with clinical signs of severe pneumonia or severe acute respiratory infection as follows: fever, cough, dyspnea, RR>30 breaths/minute, severe respiratory distress or SpO2 < 92% on room air
- 2. Child with clinical signs of pneumonia (cough or difficulty in breathing) plus at least one of the following:
 - a. Central cyanosis or SpO2 < 90%; severe respiratory distress (e.g. fast breathing, grunting, very severe chest indrawing); general danger sign: inability to breastfeed or drink, lethargy or unconsciousness, or convulsions.
 - b. Fast breathing (in breaths/min): < 2 months: > 60; 2-11 months: > 50; 1-5 years: > 40.

CRITICAL

Patients manifesting with acute respiratory distress syndrome, sepsis and/or septic shock:

- 1. Acute Respiratory Distress Syndrome (ARDS)
 - a. Patients with onset within 1 week of known clinical insult (pneumonia) or new or worsening respiratory symptoms, progressing infiltrates on chest X-ray or chest CT scan, with respiratory failure not fully explained by cardiac failure or fluid overload

2. Sepsis

- a. Adults with life-threatening organ dysfunction caused by a dysregulated host response to suspected or proven infection. Signs of organ dysfunction include altered mental status, difficult or fast breathing, low oxygen saturation, reduced urine output, fast heart rate, weak pulse, cold extremities or low blood pressure, skin mottling, or laboratory evidence of coagulopathy, thrombocytopenia, acidosis, high lactate or hyperbilirubinemia
- b. Children with suspected or proven infection and > 2 age-based systemic inflammatory response syndrome criteria (abnormal temperature [> 38.5 °C or < 36 °C); tachycardia for age or bradycardia for age if < 1year; tachypnea for age or need for mechanical ventilation; abnormal white blood cell count for age or > 10% bands), of which one must be abnormal temperature or white blood cell count.

3. Septic Shock

- a. Adults with persistent hypotension despite volume resuscitation, requiring vasopressors to maintain MAP > 65 mmHg and serum lactate level >2mmol/L
- o. Children with any hypotension (SBP < Sth centile or > 2 SD below normal for age) or two or three of the following: altered mental status; bradycardia or tachycardia (HR < 90 bpm or > 160 bpm in infants and heart rate < 70 bpm or > 150 bpm in children); prolonged capillary refill (> 2 sec) or weak pulse; fast breathing; mottled or cool skin or petechial or purpuric rash; high lactate; reduced urine output; hyperthermia or hypothermia.